Intercept Pharmaceuticals, Immunomedics Inc., and MannKind Corp. Could Be Big Movers in Health Care Today

Good morning, fellow Fools! Let's check in on the top stories in health care this morning.

Intercept continues to soar
Intercept Pharmaceuticals (NASDAQ: ICPT  ) is up big again this morning after Citigroup set a $400-a-share price target on the company today, despite the 281% jump yesterday. This upgrade represents a potential 60% upside remaining in the stock.

To recap yesterday's events, shares of Intercept soared after the company's experimental liver disease drug, obeticholic acid, showed such a strong benefit to patients compared to placebo that the trial was stopped early. Experts believe the drug could see peak sales of around $5 billion a year as a treatment for nonalcoholic steatohepatitis, or NASH, if approved by the U.S. Food and Drug Administration. Currently, there are no approved drugs for the disease, even though it is a leading cause of liver transplants in the U.S.

Should you take a closer look at Intercept? It's important to remember that these are midstage results, meaning the drug is about two-thirds of the way through the normal clinical trial process. That said, the results were so impressive and there is such an unmet medical need with NASH that it's highly likely Intercept will seek accelerated approval.

My take is that the market believes that accelerated approval is forthcoming based on these stellar results. Nonetheless, you need to realize that there is a real risk of a rejection from the FDA for accelerated approval, if the company goes that route. Just ask Sarepta Therapeutics. Put simply, nothing is a given with the FDA.

Even so, there is a better than average chance that Intercept's drug is approved sooner rather than later. In that case, today's share price could look cheap if the drug lives up to the hype. So my take is that Intercept does warrant a closer look, even after yesterday's monstrous rally.

Immunomedics continues to rally on clinical progress
Monoclonal antibody specialist Immunomedics (NASDAQ: IMMU  )  is up big in premarket this morning after announcing the start of a late-stage trial for its experimental pancreatic cancer therapy clivatuzumab. The trial will enroll up to 440 patients with metastatic pancreatic cancer, with enrollment expected to be completed by mid-2015. 

Is this story worth checking out? I believe so. The company's approach is similar to Seattle Genetics and Roche's approved antibody drug conjugates that are top-line cancer therapies, and clivatuzumab would be the first such therapy for pancreatic cancer. What's key to understand is that pancreatic cancer is notoriously difficult to treat, especially when patients fail frontline treatments. So there is an unmet medical need in this area that clivatuzumab could help to fill.

With that said, you need to understand that Immunomedics is a developmental-stage company that relies mostly on dilution for funding, and this trial won't be completed anytime soon. So you might want to wait to see how this plays out before jumping in right now. 

MannKind falling back to Earth
Shares of MannKind (NASDAQ: MNKD  ) are pulling back a fair amount in premarket this morning after yesterday's 18% jump. MannKind soared yesterday after word leaked that an FDA Advisory Committee would possibly review the company's lead clinical candidate Afrezza on April 1 of this year. The review is expected to be completed no later than April 15.

Afrezza is an inhalable, ultra-fast-acting insulin product that could dominate the insulin delivery market if approved. Last year, Afrezza completed two late-stage trials requested by the FDA that will be the main focus of the upcoming regulatory review.

So, what's my take? I think Afrezza will get approved this time around based on the strength of its late-stage trial results. In my view, the real question is whether or not the drug can gain market share against the likes of Novo Nordisk's and Eli Lilly's injectable pens that deliver fast-acting insulin. Overall, I am cautiously optimistic that MannKind will finally deliver on the promise of an inhalable insulin product that customers actually want to use. So you might want to keep tabs on this compelling story going forward. 

These three stocks might beat Intercept Pharmaceuticals, Immunomedics, and MannKind this year
 It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 10, 2014, at 2:06 PM, southcherry wrote:

    As far as IMMU goes, the statement that they will need to do a stock offering as if it were fact is not a service to the readers. They probably WILL eventually do another offering, but they currently have multiple molecules being offered for deals ("ADC's" in a hot ADC market) and they have a fairly illustrious agent working to broker the deals for them. Likely that a deal will happen first, cover the cost of all current P3 trials, and THEN, when the market raises the price of the stock considerably based on revelation of the deal(s), they will have Goldman Sachs do an offering (and you know GS will pump the stock FIRST!!). In other words, your cautionary wording is due to lack of information. That said, this stock is a heartbreaker unless you are nimble on these ramp-ups, although this time it may well be different.

  • Report this Comment On January 11, 2014, at 3:27 AM, amungiol wrote:

    IMMU has had run ups before only to disappoint and sink back into the $3 to $4 range. So, don't bet the farm just yet.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2790339, ~/Articles/ArticleHandler.aspx, 8/28/2014 11:38:33 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement